Spinogenix Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $10.6M

  • Investors
  • 4

Spinogenix General Information

Description

Operator of a biopharmaceutical company intended to restore the brain connections and functions lost in brain injury and neurodegenerative diseases. The company offers drugs to reverse synapse loss, restoring connections lost to neurodegenerative diseases and other conditions involving the central nervous system, enabling patients to regenerate synapses through their direct modulation of synaptic proteins.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1801 Century Park East
  • Suite 2400
  • Los Angeles, CA 90067
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1801 Century Park East
  • Suite 2400
  • Los Angeles, CA 90067
  • United States
+1 (858)

Spinogenix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spinogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series D) 09-Mar-2026 $10.6M Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 07-Jun-2024 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 21-Jun-2024 Completed Clinical Trials - Phase 1
6. Grant 26-Sep-2023 Completed Startup
5. Later Stage VC (Series A3) 10-Sep-2022 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 23-Feb-2021 Completed Pre-Clinical Trials
3. Seed Round 03-May-2018 Completed Pre-Clinical Trials
2. Grant 01-Jan-2018 $315K Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2016 Completed Startup
To view Spinogenix’s complete valuation and funding history, request access »

Spinogenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D-1
Series D
Series C
Series B
Series A-3
Series A-2
Series A-1 116,619 $0.000100 8% $2.25 $2.25 1x $2.25 1.22%
Seed 979,163 $0.000100 8% $1 $1 1x $1 10.21%
To view Spinogenix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Spinogenix Patents

Spinogenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026050308-A1 Benzothiazole compound for treating or preventing diabetes Pending 26-Aug-2024
WO-2026050303-A1 Methods of treating ophthalmic diseases Pending 26-Aug-2024
AU-2025228499-A1 Methods for prevention and treatment of depression Pending 29-Feb-2024
WO-2025184576-A1 Methods for prevention and treatment of depression Pending 29-Feb-2024
AU-2024244089-A1 Methods of dosing spinogenic compounds Pending 03-Apr-2023 A61K31/428
To view Spinogenix’s complete patent history, request access »

Spinogenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spinogenix Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Stead Impact Ventures and Foundation Impact Investing Minority
United States Department of War Government
U.S. Department of Health and Human Services Government
University of California, San Diego University Minority
To view Spinogenix’s complete investors history, request access »

Spinogenix FAQs

  • When was Spinogenix founded?

    Spinogenix was founded in 2016.

  • Where is Spinogenix headquartered?

    Spinogenix is headquartered in Los Angeles, CA.

  • What is the size of Spinogenix?

    Spinogenix has 5 total employees.

  • What industry is Spinogenix in?

    Spinogenix’s primary industry is Drug Discovery.

  • Is Spinogenix a private or public company?

    Spinogenix is a Private company.

  • What is the current valuation of Spinogenix?

    The current valuation of Spinogenix is .

  • What is Spinogenix’s current revenue?

    The current revenue for Spinogenix is .

  • How much funding has Spinogenix raised over time?

    Spinogenix has raised $27.5M.

  • Who are Spinogenix’s investors?

    Stead Impact Ventures and Foundation, United States Department of War, U.S. Department of Health and Human Services, and University of California, San Diego have invested in Spinogenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process